The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies

Progress in Retinal and Eye Research

Volumn 42, Issue , 2014, Pages 27-43

  Herrero Vanrell, Rocío ^a,b   Bravo Osuna, Irene ^a,b   Andrés Guerrero, Vanessa ^a,b   Vicario de la Torre, Marta ^a,b   Molina Martínez, Irene Teresa ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Controlled release; Microspheres; Ocular drug delivery; PLGA; Retina

Indexed keywords

MACROGOL; MICROSPHERE; POLYGLACTIN; DELAYED RELEASE FORMULATION; POLYMER;

ACUTE RETINAL NECROSIS; ADMINISTRATION OF DRUGS, FOOD AND CHEMICALS; CATARACT EXTRACTION; CYTOMEGALOVIRUS RETINITIS; DEGENERATIVE DISEASE; DEGRADATION; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; EYE INFECTION; GLAUCOMA; HUMAN; HYDROPHILICITY; IN VITRO STUDY; INJECTION; INSTRUMENT STERILIZATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR INFLAMMATION; INTRAVITREAL DRUG ADMINISTRATION; LIPOPHILICITY; MICROENCAPSULATION; MICRONEEDLE; NONHUMAN; OPTIC NERVE DISEASE; PATHOLOGY; PERIOCULAR DRUG ADMINISTRATION; PHOTORECEPTOR; POSTOPERATIVE COMPLICATION; POSTSURGICAL FIBROSIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REGENERATIVE MEDICINE; RETINA CELL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINAL PROGENITOR CELL; RETINITIS PIGMENTOSA; REVIEW; STEM CELL; SUBRETINAL NEOVASCULARIZATION; SUPRACHOROIDAL ADMINISTRATION; TRANSPLANTATION; UVEITIS; VITREORETINOPATHY; ADMINISTRATION AND DOSAGE; BIODEGRADABLE IMPLANT; DELAYED RELEASE FORMULATION; EYE DISEASES; PERSONALIZED MEDICINE; PROCEDURES; RETINAL DISEASES;

ABSORBABLE IMPLANTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; INDIVIDUALIZED MEDICINE; INJECTIONS, INTRAOCULAR; MICROSPHERES; POLYMERS; RETINAL DISEASES;

EID: 84906054346     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2014.04.002     Document Type: Review

References (83)

1. Algvere P., Bill A. Drainage of microspheres and RBCs from the vitreous of aphakic and phakic eyes. Arch. Ophthalmol. 1979, 97:1333-1336.
2. Amrite A.C., Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J.Pharm. Pharmacol. 2005, 57:1555-1563.
3. Amrite A.C., Ayalasomayajula S.P., Cheruvu N.P., Kompella U.B. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol. Vis. Sci. 2006, 47:1149-1160.
4. Andrés-Guerrero V., Zong M., Mihov G., Dias A., Herrero-Vanrell R. Dexamethasone Sustained Delivery From Polyesteramide Microspheres for Intraocular Administration. Influence of Sterilization 2013, Pan-American Association of Ophthalmology. Pan-American Research Day, Seattle, USA.
5. Andrieu-Soler C., Aubert-Pouessel A., Doat M., Picaud S., Halhal M., Simonutti M., Venier-Julienne M.C., Benoit J.P., Behar-Cohen F. Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol. Vis. 2005, 11:1002-1011.
6. Arango-González B., Ueffing M. Preclinical testing of compounds and intraocular drug delivery systems using an organ retinal culture. PANOPTES: challenges and new perspectives in ophthalmic applications. XXV Symposium of the European Society for Biomaterials, Madrid, Spain 2013.
7. Barcia E., Herradon C., Herrero-Vanrell R. Biodegradable additives modulate ganciclovir release rate from PLGA microspheres destined to intraocular administration. Lett. Drug. Des. 2005, 2:184-193.
8. Barcia E., Herrero-Vanrell R., Diez A., Alvarez-Santiago C., Lopez I., Calonge M. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. Exp. Eye Res. 2009, 89:238-245.
9. Bittner B., Mader K., Kroll C., Borchert H.H., Kissel T. Tetracycline-HCl-loaded poly(DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J.Control Release 1999, 59:23-32.
10. Brunner A., Mäder K., Göpferich A. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm. Res. 1999, 16:847-853.
11. Cardillo J.A., Souza-Filho A.A., Oliveira A.G. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulness for the treatment of diabetic macular edema. Arch. Soc. Esp. Oftalmol. 2006, 81:675-677. 679-681.
12. Carrasquillo K.G., Ricker J.A., Rigas I.K., Miller J.W., Gragoudas E.S., Adamis A.P. Controlled delivery of anti-VEGF aptamer EYE 001 with poly(lactic-co-glucolic) acid microspheres. Invest Ophthalmol. Vis. Sci. 2003, 44:290-299.
13. Chan I.M., Tolentino F.I., Refojo M.F., Fournier G., Albert D.M. Vitreous substitute. Experimental studies and review. Retina 1984, 4:51-59.
14. Checa-Casalengua P., Jiang C., Bravo-Osuna I., Tucker B.A., Molina-Martinez I.T., Young M.J., Herrero-Vanrell R. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J.Control Release 2011, 156:92-100.
15. Checa-Casalengua P., Jiang C., Bravo-Osuna I., Tucker B.A., Molina-Martínez I.T., Young M.J., Herrero-Vanrell R. Preservation of biological activity of glial cell line-derived neurotrophic factor (GDNF) after microencapsulation and sterilization by gamma irradiation. Int. J. Pharm. 2012, 436:545-554.
16. Chowdhury D.K., Mitra A.K. Kinetics of a model nucleoside (guanosine) release from biodegradable poly(DL-lactide-co-glycolide) microspheres: a delivery system for long-term intraocular delivery. Pharm. Dev. Technol. 2000, 5:279-285.
17. Conti B., Bucolo C., Giannavola C., Puglisi G., Giunchedi P., Conte U. Biodegradable microspheres for the intravitreal administration of acyclovir: invitro/invivo evaluation. Eur. J. Pharm. Sci. 1997, 5:287-293.
18. Delgado A., Evora C., Llabres M. Degradation of DL-PLA-methadone microspheres during invitro release. Int. J. Pharm. 1996, 140:219-227.
19. Duvvuri S., Janoria K.G., Pal D., Mitra A.K. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. J.Ocul. Pharmacol. Ther. 2007, 23:264-274.
20. Freitas S., Merkle H.P., Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J.Control Release 2005, 102:313-332.
21. Gaudana R., Ananathula H.K., Parenky A., Mitra A.K. Ocular drug delivery. AAPS J. 2010, 12:348-360.
22. Gaudio P.A. Areview of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul. Immunol. Inflamm. 2004, 12:169-192.
23. Giordano G.G., Refojo M.F., Arroyo M.H. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest Ophthalmol. Vis. Sci. 1993, 34:2743-2751.
24. Giordano G.G., Chevez-Barrios P., Refojo M.F., Garcia C.A. Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Curr. Eye Res. 1995, 14:761-768.
25. Gomes Dos Santos A.L., Bochot A., Doyle A., Tsapis N., Siepmann J., Siepmann F., Schamaler J., Besnard M., Behar-Cohen F., Fattal E. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J.Control Release 2006, 30(112):369-381.
26. Grizzi I., Garreau H., Li S., Vert M. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials 1995, 16:305-311.
27. He Y., Liu Y., Wang J., Zhang X., Lu W., Ma Z., Zhu X., Zhang Q. Cyclosporine-loaded microspheres for treatment of uveitis: invitro characterization and invivo pharmacokinetic study. Invest Ophthalmol. Vis. Sci. 2006, 47:3983-3988.
28. Henry K., Cantrill H., Fletcher C., Chinnock B.J., Balfour H.H. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am. J. Ophthalmol. 1987, 103:17-23.
29. Herrero-Vanrell R. Microparticles as drug delivery systems for the back of the eye. Drug Product Development for the Back of the Eye. American Association of Pharmaceutical Scientist 2011, 231-260. Springer New York. U.B. Kompella, H.F. Edelhauser (Eds.).
30. Herrero-Vanrell R., Cardillo J.A. Ocular pharmacokinetic, drug bioavailability and intraocular drug delivery systems 2010, 60-66. Saunders Elsevier, China. Q.D. Nguyen, E.B. Rodrigues, M.E. Farah, W.F. Mieler (Eds.).
31. Herrero-Vanrell R., Molina Martinez I.T. PLA and PLGA microparticles for intravitreal drug delivery: an overview. J.Drug. Del. Sci. Tech. 2007, 17:11-17.
32. Herrero-Vanrell, R., Refojo, M.F., 1998. U.S. Patent 5,718,922.
33. Herrero-Vanrell R., Refojo M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug. Deliv. Rev. 2001, 52:5-16.
34. Herrero-Vanrell R., Ramirez L., Fernandez-Carballido A., Refojo M.F. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, invitro release profiles, and sterilization process. Pharm. Res. 2000, 17:1323-1328.
35. Herrero-Vanrell R., Checa-Casalengua P., Molina-Martínez I.T., Tucker B.A., Young M., Bravo-Osuna I. PLGA microparticles loaded with neuroprotective agents (GDNF and BDNF). A potential treatment for glaucoma. Invest Ophthalmol Vis Sci Annual Meeting. Fort Lauderdale, FL, USA. Abstract 5978 2009.
36. Herrero-Vanrell R., Barbosa-Alfaro D., García-Gutierrez M., Fernández-Bueno I., Molina-Martínez I.T., Pastor-Jimeno J. Tolerance of juxtascleral administration of Sterilized PLGA Microparticles Unloaded and Loaded With Dexamethasone. Invest Ophthalmol Vis Sci Annual Meeting. Fort Lauderdale, FL, USA. Abstract 5300 2010.
37. Herrero-Vanrell R., Cardillo J.A., Kuppermann B.D. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin. Ophthalmol. 2011, 5:139-146.
38. Herrero-Vanrell R., Fernandez-Sanchez L., Puebla-Gonzalez M., Lax P., Bravo-Osuna I., Cuenca N. Encapsulated TUDCA PLGA microspheres for the treatment of retinitis pigmentosa. Invest Ophthalmol Vis Sci Annual Meeting. Fort Lauderdale, FL, USA. Abstract 3251 2011.
39. Herrero-Vanrell R., Vicario-de-la-Torre M., Andrés-Guerrero V., Barbosa-Alfaro D., Molina-Martinez I.T., Bravo-Osuna I. Nano and microtechnologies for ophthalmic administration, an overview. J.Drug. Del. Sci. Tech. 2013, 23:75-102.
40. Jabs D.A., Enger C., Bartlett J.G. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch. Ophthalmol. 1989, 107:75-80.
41. Jain S., Malvala P., Pallaoro M., Giuliani M., Petersen H., ÓHagan D.T., Singh M. Atwo-stage strategy for sterilization of poly(lactide-co-glycolide) particles by gamma-irradiation does not impair their potency for vaccine delivery. J.Pharm. Sci. 2011, 100:646-654.
42. Jiang C., Moore M.J., Zhang X., Klassen H., Langer R., Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol. Vis. 2007, 13:1783-1792.
43. Khoobehi B., Stradtmann M.O., Peyman G.A., Aly O.M. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. 1991 Mar, 22(3):175-180.
44. Kompella U.B., Bandi N., Ayalasomayajula S.P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol. Vis. Sci. 2003, 44:1192-1201.
45. Kwak H.W., D'Amico D.J. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol. 1992, 110:259-266.
46. Lambert B.J., Mendelson T.A., Craven M.D. Radiation and ethylene oxide terminal sterilization experiences with drug eluting stent products. AAPS Pharm. Sci. Tech. 2011, 12:1116-1126.
47. Lee W.K., Park J.Y., Yang E.H., Suh H., Kim S.H., Chung D.S., Choi K., Yang C.W., Park J.S. Investigation of the factors influencing the release rates of cyclosporin A-loaded micro- and nanoparticles prepared by high-pressure homogenizer. J.Control Release 2002, 84:115-123.
48. Li S. Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids. J.Biomed. Mater. Res. 1999, 48:342-353.
49. Martinez-Sancho C., Herrero-Vanrell R., Negro S. Poly (D,L-lactide-co-glycolide) microspheres for long-term intravitreal delivery of aciclovir: influence of fatty and non-fatty additives. J.Microencapsul. 2003, 20:799-810.
50. Martinez-Sancho C., Herrero-Vanrell R., Negro S. Optimisation of aciclovir poly(D,L-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study. Int. J. Pharm. 2004, 273:45-56.
51. Martinez-Sancho C., Herrero-Vanrell R., Negro S. Study of gamma-irradiation effects on aciclovir poly(D,L-lactic-co-glycolic) acid microspheres for intravitreal administration. J.Control Release 2004, 99:41-52.
52. Martinez-Sancho C., Herrero-Vanrell R., Negro S. Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release. Int. J. Pharm. 2006, 326:100-106.
53. Miller R.A., Brady J.M., Cutright D.E. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J.Biomed. Mater. Res. 1977, 11:711-719.
54. Mohanan D., Gander B., Kundig T.M., Johansen P. Encapsulation of antigen in poly(D,L-lactide.co-glycolide) microspheres proects from harmful effects of gamma-irradiation as assessed in mice. Eur. J. Pharm. Biopharm. 2012, 80:274-281.
55. Montanari L., Costantini M., Signoretti E.C., Valvo L., Santucci M., Bartolomei M., Fattibene P., Onori S., Faucitano A., Conti A., Genta I. Gamma irradiation effects on poly(DL,-lactide-co-glycolide) microspheres. J.Control Release 1998, 56:219-229.
56. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol. Vis. Sci. 1991, 32:1785-1790.
57. Moritera T., Ogura Y., Yoshimura N., Honda Y., Wada R., Hyon S.H., Ikada Y. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol. Vis. Sci. 1992, 33:3125-3130.
58. Nijsen J.F., van Het Schip A.D., van Steenbergen M.J., Zielhuis S.W., Kroon-Batenburg L.M., van de Weert M., van Rijk P.P., Hennink W.E. Influence of neutron irradiation on holmium acetylacetonate loaded poly(L-lactic acid) microspheres. Biomaterials 2002, 23:1831-1839.
59. Paganelli F., Cardillo J.A., Melo L.A., Lucena D.R., Silva A.A., Oliveira A.G., Hofling-Lima A.L., Nguyen Q.D., Kuppermann B.D., Belfort R. Asingle intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery. Invest Ophthalmol. Vis. Sci. 2009, 50:3041-3047.
60. Paganelli F., Cardillo J.A., Dare A.R., Melo L.A., Lucena D.R., Silva A.A., Oliveira A.G., Pizzolitto A.C., Lavinsky D., Skaf M., Souza-Filho A.A., Hofling-Lima A.L., Nguyen Q.D., Kuppermann B.D., Herrero-Vanrell R., Belfort R. Controlled transscleral drug delivery formulations to the eye: establishing new concepts and paradigms in ocular anti-inflammatory therapeutics and antibacterial prophylaxis. Expert Opin. Drug. Deliv. 2010, 7:955-965.
61. Patel S.R., Lin A.S., Edelhauser H.F., Prausnitz M.R. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm. Res. 2011, 28:166-176.
62. Patel S.R., Berezovsky D.E., McCarey B.E., Zarnitsyn V., Edelhauser H.F., Prausnitz M.R. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol. Vis. Sci. 2012, 53:4433-4441.
63. Piano I., Novelli E., Gasco P., Ghidoni R., Strettoi E., Gargini C. Cone survival and preservation of visual acuity in an animal model of retinal degeneration. Eur. J. Neurosci. 2013, 37:1853-1862.
64. Ranta V.P., Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv. Drug. Deliv. Rev. 2006, 58:1164-1181.
65. Rincon A.C., Molina-Martinez I.T., de Las Heras B., Alonso M., Bailez C., Rodriguez-Cabello J.C., Herrero-Vanrell R. Biocompatibility of elastin-like polymer poly(VPAVG) microparticles: invitro and invivo studies. J.Biomed. Mater. Res. A 2006, 78:343-351.
66. Rodrigues E.B., Grumann A., Penha F.M., Shiroma H., Rossi E., Meyer C.H., Stefano V., Maia M., Magalhaes O., Farah M.E. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J.Ocul. Pharmacol. Ther. 2011, 27:197-203.
67. Rodriguez A., Calonge M., Pedroza-Seres M., Akova Y.A., Messmer E.M., D'Amico D.J., Foster C.S. Referral patterns of uveitis in a tertiary eye care center. Arch. Ophthalmol. 1996, 114:593-599.
68. Rojas B., de Hoz R., Ramírez A., Salazar J.J., Gallego B., Triviño A., Andrés-Guerrero V., Herrero-Vanrell R., Mihov G., Dias A., Zong M., Ramírez J.M. Handling of PEA Microparticles for invivo intraocular injections. XXV Symposium of the European Society for Biomaterials 2013, Spain, Madrid, OP142.
69. Saishin Y., Silva R.L., Callahan K., Schoch C., Ahlheim M., Lai H., Kane F., Brazzell R.K., Bodmer D., Campochiaro P.A. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol. Vis. Sci. 2003, 44:4989-4993.
70. Sintzel M.B., Schwach-Abdellaoui K., Mäder K., Stösser R., Heller J., Tabatabay C., Gurny R. Influence of irradiation sterilization on a semi-solid poly(ortho ester). Int. J. Pharm. 1998, 175:165-176.
71. Srinivasan C., Katare Y.K., Muthukumaran T., Panda A.K. Effect of additives on encapsulation efficiency, stability and bioactivity of entrapped lysozyme from biodegradable polymer particles. J.Microencapsul. 2005, 22:127-138.
72. Strettoi E., Gargini C., Novelli E., Sala G., Piano I., Gasco P., Ghidoni R. Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 2010, 26:18706-18711.
73. Szurman P., Kaczmarek R., Spitzer M.S., Jaissle G.B., Decker P., Grisanti S., Henke-Fahle S., Aisenbrey S., Bartz-Shmidt K.U. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp. Eye Res. 2006 Sep, 83(3):584-592. Epub 2006 May 8.
74. Tan E., Ding X., Saadi A., Agarwal N., Haash M.I., Al-Ulbaidi M.R. Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol. Vis. Sci. 2004, 45:764-768.
75. Urata T., Arimori K., Nakano H. Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J.Control Release 1999, 58:133-141.
76. van Wijngaarden P., Qureshi S.H. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin. Exp. Optom. 2008, 91:427-437.
77. Veloso A.A., Zhu Q., Herrero-Vanrell R., Refojo M.F. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Vis. Sci. 1997, 38:665-675.
78. Visscher G.E., Robison R.L., Maulding H.V., Fong J.W., Pearson J.E., Argentieri G.J. Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J.Biomed. Mater. Res. 1985, 19:349-365.
79. Yaman A. Alternative methods of terminal sterilization for biologically active macromolecules. Curr. Opin. Drug. Discov. Devel. 2001, 4:760-763.
80. Yao J., Tucker B.A., Zhang X., Checa-Casalengua P., Herrero-Vanrell R., Young M.J. Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials 2011, 32:1041-1050.
81. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., Honda Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin Eye Res. 2004, 23:253-281.
82. Yasukawa T., Tabata Y., Kimura H., Ogura Y. Recent advances in intraocular drug delivery systems. Recent Pat. Drug. Deliv. Formul. 2011, 5:1-10.
83. Zimmer A., Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv. Drug. Deliv. Rev. 1995, 16:61-73.